DCTH press release
Key Highlights
- ➤CS-PHP cohort delivered 66.7% objective response and 75% disease control rates
- ➤Median hepatic progression-free survival reached 18.4 months in 12-patient cohort
- ➤Median overall survival was 28 months after median three CS-PHP cycles
- ➤Serious adverse events occurred in three patients; no treatment-related deaths reported
- ➤Delcath will present Phase 2 trial updates and independent uveal melanoma comparison at ESMO 2026
Expert Statements
Heather McArthur, MD, MPH; Global Principal Investigator, UT Southwestern Medical Center
“DELUMA: An Open-Label, Randomized Phase II Study of Melphalan/HDS Induction Followed by Standard Therapy vs Standard Therapy Alone in Patients with Liver-Dominant Metastatic Breast Cancer”
Marwan Fakih, MD; Global Principal Investigator, City of Hope
“Del-Liver Phase 2 trial in metastatic colorectal cancer – update presented by Global Principal Investigator Marwan Fakih, MD, City of Hope”
Heather McArthur, MD, MPH; Global Principal Investigator, UT Southwestern Medical Center
“Deluma Phase 2 trial in metastatic breast cancer – update presented by Global Principal Investigator Heather McArthur, MD, MPH, UT Southwestern Medical Center”
Cato Boreel, Dutch Institute for Clinical Auditing (Dutch Melanoma Treatment Registry)
“Liver-metastatic uveal melanoma comparison: melphalan hepatic delivery (PHP) + ipilimumab/nivolumab versus tebentafusp”
Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The Company also highlighted the publication of an independent, investigator-led analysis of percutaneous hepatic perfusion (PHP) with melphalan using the CHEMOSAT® Hepatic Delivery System in patients with liver-dominant metastatic uveal melanoma (mUM).
Get started
Create a free account to read the full story.